PE20061399A1 - N-oxido de piridina fluorados moduladores de la trombina y procesos para la n-oxidacion de heteroarilos nitrogenados - Google Patents

N-oxido de piridina fluorados moduladores de la trombina y procesos para la n-oxidacion de heteroarilos nitrogenados

Info

Publication number
PE20061399A1
PE20061399A1 PE2006000404A PE2006000404A PE20061399A1 PE 20061399 A1 PE20061399 A1 PE 20061399A1 PE 2006000404 A PE2006000404 A PE 2006000404A PE 2006000404 A PE2006000404 A PE 2006000404A PE 20061399 A1 PE20061399 A1 PE 20061399A1
Authority
PE
Peru
Prior art keywords
oxide
fluorates
nitrogenated
heteroaryls
pyridine
Prior art date
Application number
PE2006000404A
Other languages
English (en)
Spanish (es)
Inventor
Kreutter Kevin
Tianbao Lu
Christopher Teleha
Xizhen Zhu
Mark Player
Yu Kai Lee
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20061399A1 publication Critical patent/PE20061399A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
PE2006000404A 2005-04-20 2006-04-18 N-oxido de piridina fluorados moduladores de la trombina y procesos para la n-oxidacion de heteroarilos nitrogenados PE20061399A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67313105P 2005-04-20 2005-04-20
US11/385,056 US7262210B2 (en) 2005-04-20 2006-03-21 Fluorinated pyridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls

Publications (1)

Publication Number Publication Date
PE20061399A1 true PE20061399A1 (es) 2007-02-05

Family

ID=36685688

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000404A PE20061399A1 (es) 2005-04-20 2006-04-18 N-oxido de piridina fluorados moduladores de la trombina y procesos para la n-oxidacion de heteroarilos nitrogenados

Country Status (12)

Country Link
US (1) US7262210B2 (enExample)
EP (1) EP1879864A1 (enExample)
JP (1) JP2008536918A (enExample)
KR (1) KR20080004554A (enExample)
CN (1) CN101228129A (enExample)
AU (1) AU2006240423A1 (enExample)
BR (1) BRPI0610506A2 (enExample)
CA (1) CA2605480A1 (enExample)
MX (1) MX2007013198A (enExample)
PE (1) PE20061399A1 (enExample)
TW (1) TW200718688A (enExample)
WO (1) WO2006115652A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829584B2 (en) * 2006-03-21 2010-11-09 Janssen Pharmaceutica Nv Pyridines and pyridine N-oxides as modulators of thrombin
US7875636B2 (en) 2006-04-12 2011-01-25 Merck Sharp & Dohme Corp. Pyridyl amide T-type calcium channel antagonists
KR20100072266A (ko) 2007-10-24 2010-06-30 머크 샤프 앤드 돔 코포레이션 헤테로사이클 페닐 아미드 t-형 칼슘 채널 길항제
US9884822B2 (en) 2012-02-09 2018-02-06 Arch Chemicals, Inc. Process for the preparation of 1-hydroxy-6-substituted pyridones
WO2015183709A1 (en) * 2014-05-28 2015-12-03 Merck Sharp & Dohme Corp. Factor xia inhibitors
CN105037280B (zh) * 2015-06-23 2017-09-29 西安近代化学研究所 一种 2,6‑二氨基‑3,5‑二硝基吡嗪‑1‑氧化物的合成方法
BR112018008506B8 (pt) * 2015-10-29 2023-12-05 Merck Sharp & Dohme Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos
US10143681B2 (en) 2016-08-22 2018-12-04 Merck Sharp & Dohme Corp. Factor XIa inhibitors
AU2018338194B2 (en) 2017-09-22 2021-07-08 Becton, Dickinson And Company 4% trisodium citrate solution for use as a catheter lock solution
CN110818629A (zh) * 2019-12-05 2020-02-21 杭州勇诚睿生物科技有限公司 一种合成氟代异烟酸衍生物的方法
AU2022212785A1 (en) * 2021-01-28 2023-07-27 Merck Sharp & Dohme Llc Factor xia inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187379A (en) 1978-11-13 1980-02-05 Warner-Lambert Company 3-Aryloxy-2-pyridinecarbonitrile 1-oxide compounds
DE3918834A1 (de) 1989-01-26 1990-08-02 Bayer Ag Aryl- und heteroarylethanol-pyridylalkylamine, verfahren zu ihrer herstellung und ihre verwendung als leistungsfoerderer bei tieren und als mittel gegen adipositas
DK220890D0 (da) 1990-09-14 1990-09-14 Ole Buchardt Fremgangsmaade til fremstilling af c-terminalt amiderede peptider
DE69210091T2 (de) 1991-05-31 1996-10-02 Sumitomo Pharma Leukotrien-B4-Antagonisten
FR2686084B1 (fr) 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
DE59305738D1 (de) 1992-11-29 1997-04-17 Hoechst Ag Verfahren zur Herstellung von halogenierten Benzoesäuren
TR199801255T2 (xx) 1995-12-29 1998-10-21 Smithkline Beecham Corporation Vitronektin resept�r antagonistleri.
IL138245A0 (en) 1998-03-10 2001-10-31 Smithkline Beecham Corp Vitronectin receptor antagonists
CA2430037A1 (en) 2000-11-20 2002-05-30 Michael S. South Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
US6610701B2 (en) 2001-02-09 2003-08-26 Merck & Co., Inc. Thrombin inhibitors
US20030158218A1 (en) * 2001-12-21 2003-08-21 Nantermet Philippe G. Thrombin inhibitors
US7550474B2 (en) 2003-04-10 2009-06-23 Johnson & Johnson Pharmaceuticals Research & Development, L.L.C. Substituted phenyl acetamides and their use as protease inhibitors
WO2005010011A2 (en) 2003-07-15 2005-02-03 Xenoport, Inc. Methods of synthesis of acyloxyalkyl compounds

Also Published As

Publication number Publication date
US20060241148A1 (en) 2006-10-26
AU2006240423A1 (en) 2006-11-02
TW200718688A (en) 2007-05-16
MX2007013198A (es) 2008-03-24
KR20080004554A (ko) 2008-01-09
WO2006115652A1 (en) 2006-11-02
JP2008536918A (ja) 2008-09-11
CA2605480A1 (en) 2006-11-02
CN101228129A (zh) 2008-07-23
US7262210B2 (en) 2007-08-28
BRPI0610506A2 (pt) 2010-06-29
EP1879864A1 (en) 2008-01-23

Similar Documents

Publication Publication Date Title
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
NO20081013L (no) 7-substituerte aza-indazoler, sammensetninger inneholdende disse, produksjonsmetode og anvendelse derav
NO20074666L (no) Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer
NO20092050L (no) Nye sulfonamidderivater som bradykininantagonister
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
NO20092692L (no) MAPK/ERK kinaseinhibitorer
EA200970156A1 (ru) Пиридизиноновые производные
NO20076306L (no) Bicykliske derivater som modulatorer av ionekanaler
ECSP045064A (es) Agonistas receptores de trombina
ECSP077836A (es) Compuestos mejorados farmacocinéticamente
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
CY1106343T1 (el) Παραγωγα νικοτιναμιδιου χρησιμα σαν pde4 αναστολεις
EA200800240A1 (ru) Производные тиазола в качестве активатора амфк
NO20082209L (no) Homo- og heterocykliske forbindelser anvendbare som CETP-inhibitorer
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
MX2010003849A (es) Antagonistas de cgrp.
NO20085212L (no) Nye pyridinanaloger
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
CY1114354T1 (el) Νεα παραγωγα βενζαμιδιου ως ανταγωνιστες βραδυκινινης
NO20092341L (no) Substituerte piperidiner inneholdende et heteroarylamid eller en heteroarylfenyl gruppe
NO20080468L (no) Diazepinokinoliner, synteser av disse samt intermediater
NO20082105L (no) Pyrazoloisokinolinderivater

Legal Events

Date Code Title Description
FC Refusal